Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insurance Group Regulatory News (SBRE)

Share Price Information for Sabre Insurance Group (SBRE)

Share Price is delayed by 15 minutes
Get Live Data
157.60    3.80 (2.47%)
Bid:
157.60
Ask:
158.00
Spread: 0.40 (0.254%)
Market Cap: £385.03m
SBRE Live PriceLast checked at - London Stock Exchange

Intraday Sabre Insurance Group Share Chart

Trading Update

21 May 2026 07:00

RNS Number : 1667F
Sabre Insurance Group PLC
21 May 2026
 

Sabre Insurance Group plc

Trading Update

Return to growth in premium, continued focus on pricing discipline

Full-year guidance reiterated; Ambition 2030 on track

Sabre Insurance Group plc (the "Group" or "Sabre"), one of the UK's leading motor insurance underwriters, today provides an update on trading for the period from 1 January 2026 to 30 April 2026 ahead of its Annual General Meeting ("AGM") later this morning.

Unaudited

Unaudited

 

4 months ended

4 months ended

 

 30 Apr 2026

 30 Apr 2025

Gross written premium - Motor Vehicle

£68.9m

£58.1m

Gross written premium - Motorcycle

£4.9m

£3.3m

Gross written premium - Taxi

£2.5m

£4.7m

Gross written premium - Total

£76.3m

£66.1m

Business highlights for the first four months of 2026

‒ Total gross written premium up over 15%, with Motor Vehicle gross written premium over 18% up on the same period in 2025

‒ Motorcycle premium up c.48% year-on-year reflecting the continued roll-out of our "Sabre Direct" product, while lower Taxi premium reflects continued unattractive market conditions

‒ Increased competitiveness due to revision of forward-looking claims inflation assumptions towards the end of 2025, against a backdrop of stabilising market prices

‒ Level of premium growth for the rest of the year will be influenced by market pricing dynamics as we continue to exercise pricing discipline to cover claims inflation

‒ Post-dividend solvency capital ratio remains strong, reflecting continued organic capital generation

‒ Ambition 2030 initiatives progressing. Testing of new pricing initiatives continues successfully, as does the roll-out of the "Sabre Direct" motorcycle product

Market trends

‒ Evidence of market prices having stabilised, with some recent signs of increases

‒ Claims inflation remains at mid-single digits; however we will continue to monitor potential short- and longer-term cost pressures resulting from geopolitical developments

Full-year guidance reiterated

‒ Reiterate guidance given at full-year 2026 results:

‒ Continue to expect year-on-year growth in Gross Written Premium. The rate of growth will be influenced by how quickly the wider market moves to cover claims inflation

‒ Continue to anticipate profit slightly ahead of 2025 underpinned by sustained pricing discipline during ongoing competitive market conditions

‒ Expect strong undiscounted net insurance margins in 2026, within our target 18% to 22% range

‒ Ambition 2030 remains on track. In-line with our planned timetable, testing will continue this year with modest impact on 2026 as our initiatives start to take effect with more significant impacts from 2027 onwards

 

Geoff Carter, Chief Executive Officer of Sabre, commented:

"2026 has got off to a strong start for Sabre, with gross written premium materially ahead of last year despite conditions remaining competitive in our target markets. As reported in our recent full-year results presentation, we were able to enhance our competitiveness towards the end of 2025 following evidence-based revisions to our forward-looking claims inflation assumptions. This has driven growth this year whilst maintaining our written margins within our target range. This has underlined our confidence in our ability to grow this year.

We still see claims cost inflation at mid-single digits but are mindful of the potential impact of geopolitical developments. We continue to cover identifiable drivers of claims inflation and will not hesitate to increase prices if required to address any additional emerging inflation risks.

We have continued to progress our Ambition 2030 initiatives. We have expanded our Sabre Direct motorcycle product as we have increased our confidence in its underlying profitability and have continued testing of our differentiated pricing approach within Motor Vehicle. As we have previously reported, we do not expect an immediate significant impact on income from these initiatives as we test, learn and evaluate, in order to prioritise maintaining overall profitability.

We remain confident in our outlook for 2026 and reiterate that we expect to grow topline premium and deliver a strong profit for 2026, slightly above that in 2025. This will put us on a strong footing for the future enabling us to deliver good capital returns to our shareholder.

I would like to thank all our employees for their continued hard work and dedication."

 

Investor enquiries

01306 747 272

Sabre Insurance Group plc

Geoff Carter / Adam Westwood

Media enquiries

020 7260 2700

Teneo

sabre@teneo.com

James Macey White / Ffion Dash

 

LEI Code: 2138006RXRQ8P8VKGV98

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSEDFASEMSEDI
Date   Source Headline
13th Apr 20224:18 pmRNSNotice of AGM
12th Apr 20223:34 pmRNSDirector/PDMR Shareholding
8th Apr 20228:42 amRNSDirector/PDMR Shareholding
1st Apr 20227:13 amRNSDividend Declaration
1st Apr 20227:00 amRNSBoard Appointment
22nd Mar 20227:00 amRNSFinal Results
14th Mar 20221:22 pmRNSDirector Declaration
11th Mar 20221:50 pmRNSDirector/PDMR Shareholding
22nd Feb 20227:00 amRNSNotice of Results
21st Feb 202212:31 pmRNSHolding(s) in Company
11th Feb 202211:34 amRNSDirector/PDMR Shareholding
28th Jan 20227:00 amRNSNew Contract with Freeway Insurance Services Ltd
11th Jan 20222:27 pmRNSDirector/PDMR Shareholding
13th Dec 20211:37 pmRNSDirector/PDMR Shareholding
9th Dec 20217:00 amRNSAppointment of new additional broker
29th Nov 20217:00 amRNSDirectorate Change
11th Nov 20211:20 pmRNSDirector/PDMR Shareholding
10th Nov 20217:00 amRNSNew Contract as Exclusive Underwriter to MCE
5th Nov 202111:58 amRNSDirector/PDMR Shareholding
14th Oct 20212:27 pmRNSDirector/PDMR Shareholding
14th Oct 202111:41 amRNSDirector/PDMR Shareholding
14th Oct 20217:00 amRNSQ3 Trading Update
12th Oct 202112:06 pmRNSDirector/PDMR Shareholding
12th Oct 202112:02 pmRNSDirector Declaration
7th Oct 20217:00 amRNSNotice of Trading Update
17th Sep 20212:34 pmRNSDirector/PDMR Shareholding
17th Sep 20212:33 pmRNSDirector/PDMR Shareholding
13th Sep 202111:55 amRNSDirector/PDMR Shareholding
11th Aug 20219:51 amRNSDirector/PDMR Shareholding
30th Jul 202110:15 amRNSDirector/PDMR Shareholding
28th Jul 20213:14 pmRNSDirector/PDMR Shareholding
27th Jul 20217:00 amRNSHalf-year Report
13th Jul 202111:24 amRNSDirector/PDMR Shareholding
13th Jul 20217:00 amRNSNotice of Results
6th Jul 202111:00 amRNSHolding(s) in Company
2nd Jul 202112:50 pmRNSDirector/PDMR Shareholding
29th Jun 202111:39 amRNSHolding(s) in Company
22nd Jun 20213:46 pmRNSHolding(s) in Company
11th Jun 202110:53 amRNSDirector/PDMR Shareholding
21st May 20212:28 pmRNSDirector/PDMR Shareholding
21st May 20212:05 pmRNSDirector/PDMR Shareholding
21st May 202110:34 amRNSDirector/PDMR Shareholding
19th May 202112:49 pmRNSHolding(s) in Company
14th May 202111:46 amRNSResults of Annual General Meeting
14th May 20217:00 amRNSTrading Statement
11th May 20211:20 pmRNSDirector/PDMR Shareholding
22nd Apr 202110:00 amRNSDirector/PDMR Shareholding Replacement
22nd Apr 20219:51 amRNSDirector/PDMR Shareholding
14th Apr 20219:01 amRNSDirector/PDMR Shareholding
13th Apr 202111:12 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.